Day 1  March 07, 2016

08:00-09:00  Registrations

Burgos

09:00-09:25  Opening Ceremony

Keynote Forum

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:25-09:30</td>
<td>Introduction</td>
<td>Volkmart Weissig</td>
<td>Midwestern University College of Pharmacy Glendale, USA</td>
</tr>
<tr>
<td>09:30-09:55</td>
<td></td>
<td>Peter Krajcsi</td>
<td>Solvo Biotechnology, Hungary</td>
</tr>
<tr>
<td>09:55-10:00</td>
<td></td>
<td>Costas Kiparissides</td>
<td>Aristotle University of Thessaloniki, Greece</td>
</tr>
</tbody>
</table>

Networking & Refreshments Break 10:20-10:35 @ Salamanca

10:35-11:00  Felix Kratz
             CytrRx Corporation, Germany

11:00-11:25  Amiram Goldblum
             The Hebrew University of Jerusalem, Israel

Track 5: Nanotechnology in Drug Delivery Systems
Session Chair: Volkmart Weissig, Midwestern University College of Pharmacy Glendale, USA

11:25-11:45  Mucus permeating nanocarriers for the oral delivery of biomolecules
             Costas Kiparissides, Aristotle University of Thessaloniki, Greece

11:45-12:05  Mitochondria-targeted nano drug delivery systems
             Volkmart Weissig, Midwestern University College of Pharmacy Glendale, USA

12:05-12:25  Preparation of novel nano, micro and macro drug delivery systems via Electrohydrodynamic (EHDA) technologies
             Zeeshan Ahmad, De Montfort University, UK

12:25-12:45  Nanometronomic treatment of breast cancer with Doxorubicin loaded H-Ferritin prevents drug resistance and circumvents cardiotoxicity
             Serena Mazzucchelli, University of Milan, Italy

12:45-13:05  Paromomycin liposomes - An alternative strategy for treatment of infectious diseases
             Maria Manuela Gasper, University of Lisbon, Portugal

Lunch Break 13:05-13:50 @ Salamanca

13:50-14:10  Local delivery of nanomedicines-loaded hydrogel for the treatment of glioblastoma
             Fabienne Danhier, Louvain Drug Research Institute, Belgium

14:10-14:30  Novel targeted non-RGD cyclic peptide drug conjugates for treatment of human metastatic melanoma
             Gary Gellerman, Ariel University, Israel

14:30-14:50  Pitavastatin-containing nanoemulsions: Preparation, characterization and in-vitro cytotoxicity
             Yucel Baspinar, Ege University, Turkey

14:50-15:10  Food effects on gastrointestinal transit properties of Amphotericin B solid lipid nanoparticles
             Nashiru Billa, University of Nottingham, Malaysia

15:10-15:30  Nanotechnology: A challenge in traditional medicine
             B B Barik, Jazan University, KSA

15:30-15:50  New standards and regulations of pharmacy practice in Saudi Arabia
             Yusef Alomi, Ministry of Health, KSA

15:50-16:10  Nanobiocomposite for dual stimuli-responsive smart release of insulin using a novel high effective surface area functionalized gold nanoparticle-polypyrrole
             Ehsan Shamael, Tarbiat Modares University, Iran

Networking & Refreshments Break 16:10-16:25 @ Salamanca

Track 4: Drug Targeting
Session Chair: Volkmart Weissig, Midwestern University College of Pharmacy Glendale, USA
Session Co-Chair: Osama Ibrahim, Bio Innovation, USA

16:25-16:45  The history of bioprocess technology in drug discovery and its future perspectives
             Osama Ibrahim, Bio Innovation, USA

16:45-17:05  iRGD, a tumor-penetrating peptide for tumor-specific drug delivery
             Tatiana Hurtado de Mendoza, Sanford Burnham Prebys Medical Discovery Institute, USA
17:05-17:25 **Cell-selective delivery of Interferon gamma peptidomimetic inhibits chronic liver fibrosis and tumor angiogenesis in vivo**  
Ruchi Bansal, University of Twente, Netherlands

17:25-17:45 **Design and synthesis of novel non CYP 2D6 mediated Tamoxifen analogues**  
Nermin S Ahmed, University in Cairo, Egypt

17:45-18:05 **Looking to the future: Clinical pharmacy services in Saudi Arabia**  
Yousef Alomi, Ministry of Health, KSA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution/University</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:25</td>
<td><strong>Keynote Forum</strong></td>
<td>Joel Richard</td>
<td>IPSEN, France</td>
</tr>
<tr>
<td>09:25-09:50</td>
<td><strong>Keynote Forum</strong></td>
<td>Kang Choon Lee</td>
<td>SungKyunKwan University, Republic of South Korea</td>
</tr>
</tbody>
</table>

**Panel Discussion**

**Day 2**  
**March 08, 2016**  
**Burgos**

**Track 1: Pre-formulation Considerations**

**Track 2: Formulation Aspects for Various Routes**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution/University</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:50-10:10</td>
<td><strong>Predicting the solubility advantage of amorphous pharmaceuticals</strong></td>
<td>Gabriele Sadowski</td>
<td>TU Dortmund, Germany</td>
</tr>
<tr>
<td>10:10-10:30</td>
<td><strong>Formulation of nutraceuticals and dietary supplements: Formulation and regulatory challenges</strong></td>
<td>Shilpa Raut</td>
<td>Amway, USA</td>
</tr>
<tr>
<td>10:30-10:50</td>
<td><strong>The role of preformulation in the choice of rectal formulation : Case study of Ceftriaxone</strong></td>
<td>Tina Kauss</td>
<td>University of Bordeaux, France</td>
</tr>
</tbody>
</table>

**Networking & Refreshments Break 10:50-11:05 @ Salamanca**

**Track 12: Smart Drug Delivery Systems**

**Track 13: Delivery Methods for Peptides and Biologics**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution/University</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-13:50</td>
<td><strong>Thermally targeted delivery of anticancer therapeutic peptides using elastin-like biopolymers</strong></td>
<td>Drazen Raucher</td>
<td>University of Mississippi Medical Center, USA</td>
</tr>
<tr>
<td>13:50-14:10</td>
<td><strong>Polymeric nanoparticles for the pulmonary delivery of miRNA to treat Chronic Obstructive Pulmonary Disease (COPD)</strong></td>
<td>Gillian Hutchison</td>
<td>Liverpool John Moores University, UK</td>
</tr>
<tr>
<td>14:10-14:30</td>
<td><strong>Microneedle delivery: A novel and minimally-invasive drug delivery system to overcome limitations of hypodermic needles</strong></td>
<td>Shayan F Lahiji</td>
<td>Yonsei University, Republic of South Korea</td>
</tr>
<tr>
<td>14:30-14:50</td>
<td><strong>Functionalized near-infrared quantum dots for biological applications</strong></td>
<td>Shanmugavel Chinnathambi</td>
<td>National Institute for Materials Science, Japan</td>
</tr>
<tr>
<td>14:50-15:10</td>
<td><strong>Bicosomes: A smart skin drug delivery platform</strong></td>
<td>Rafael Bernad</td>
<td>Bicosome S.L., Spain</td>
</tr>
</tbody>
</table>

**Lunch Break 12:45-13:30 @ Salamanca**

**Young Researchers Forum**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution/University</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:10-15:25</td>
<td><strong>Challenges and advances in oral drug delivery using lipid-based nanoparticles</strong></td>
<td>Ana Rutes Neves</td>
<td>University of Porto, Portugal</td>
</tr>
<tr>
<td>15:25-15:40</td>
<td><strong>Novel Alginate-Chitosan aerogel fibers for potential wound healing applications</strong></td>
<td>Vanessa Gonçalves</td>
<td>IBET, Portugal</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker</td>
<td>Institution</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
<td>--------------------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>15:40-15:55</td>
<td>Cream formulation impact on topical administration of engineered colloidal nanoparticles</td>
<td>Benedetta Santini</td>
<td>University of Milano-Bicocca, Italy</td>
</tr>
<tr>
<td>16:10-16:25</td>
<td>The PK-Eye: A novel in vitro aqueous flow model to evaluate ocular pharmacokinetics</td>
<td>Sahar Awwad</td>
<td>UCL School of Pharmacy, UK</td>
</tr>
<tr>
<td>16:25-16:40</td>
<td>Cationic derivatives of polyisoprenoid alcohols for liposomal drug delivery</td>
<td>Olga Gawrys</td>
<td>Mossakowski Medical Research Centre PAS, Poland</td>
</tr>
<tr>
<td>16:40-16:55</td>
<td>Polymeric particulated carriers in drug delivery: Obtention, study and characterization</td>
<td>Merari Chevalier</td>
<td>CoMP-INTEMA- Universidad Nacional de Mar del Plata, Argentina</td>
</tr>
<tr>
<td>16:55-17:10</td>
<td>Cell incorporation studies with ( ^{99}\text{Tc} ) labeled methotrexate loaded chitosan nanoparticles for breast cancer diagnosis</td>
<td>Meliha Ekinici</td>
<td>Ege University, Turkey</td>
</tr>
<tr>
<td>17:10-17:25</td>
<td>Novel anticancer agent, SQAP, binds to focal adhesion kinase and modulates its activity</td>
<td>Jesus Izaguirre Carbonell</td>
<td>Tokyo University of Science, Japan</td>
</tr>
</tbody>
</table>

**Poster Presentations 16:00-18:00 @ Salamanca**

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>PNDDS01</td>
<td>Flurbiprofen 8.75 mg sore throat spray: Characteristics and performance</td>
<td>David Veale</td>
<td>Reckitt Benckiser Health Care Ltd, UK</td>
</tr>
<tr>
<td>PNDDS02</td>
<td>Self emulsifying drug delivery system (SEDDS) applied to rectal delivery for absorption enhancement of class III BCS drug</td>
<td>Tina Kauss</td>
<td>University of Bordeaux, Italy</td>
</tr>
<tr>
<td>PNDDS03</td>
<td>Polymer nanocapsules for the intracellular delivery of hydrophobic and hydrophilic anticancer drugs</td>
<td>Dolores Torres</td>
<td>University of Santiago de Compostela, Spain</td>
</tr>
<tr>
<td>PNDDS04</td>
<td>Polymeric matrixes for the controlled release of peptide-loaded chitosan nanoparticles</td>
<td>Desiree Teijeiro</td>
<td>University of Santiago de Compostela, Spain</td>
</tr>
<tr>
<td>PNDDS05</td>
<td>Drug loaded in situ hydrogels for rheumatoid arthritis treatment</td>
<td>Nataliya Storozhylova</td>
<td>University of Santiago de Compostela, Spain</td>
</tr>
<tr>
<td>PNDDS06</td>
<td>Reduction of SKOV-3 cells viability induced by CBD: in vitro evaluation and design of PLGA multiparticulate systems loaded with CBD</td>
<td>Ana Isabel Fraguas Sanchez</td>
<td>Complutense University of Madrid, Spain</td>
</tr>
<tr>
<td>PNDDS07</td>
<td>When academia and industry walk together: Projects and services for pharmaceutical companies in the Faculty of Pharmacy of the University of Barcelona</td>
<td>Marc Suné-Pou</td>
<td>University of Barcelona, Spain</td>
</tr>
<tr>
<td>PNDDS08</td>
<td>Study on different penetrability of nano and microparticles</td>
<td>Melania F Munteanu</td>
<td>Vasile Goldis West University Arad, Romania</td>
</tr>
<tr>
<td>PNDDS09</td>
<td>Delivery of Insulin encapsulated microneedles through a novel applicator in a minimal invasive manner</td>
<td>Shayan F Lahiji</td>
<td>Yonsei University, Republic of South Korea</td>
</tr>
<tr>
<td>PNDDS10</td>
<td>NanoZYME technique applied to antioxidant enzyme, SOD, has high potential in the treatment of diseases related to oxidative stress</td>
<td>Anton Aleksashkin</td>
<td>Lomonosov Moscow State University, Russia</td>
</tr>
<tr>
<td>PNDDS11</td>
<td>Dissolution method development: R&amp;D and QC holding hands</td>
<td>Ana Mafalda Paiva</td>
<td>Hovione PharmaScience Ltd., Portugal</td>
</tr>
<tr>
<td>PNDDS12</td>
<td>Ciprofloxacin loaded nano-spanlastics for ototopical non-invasive delivery to the middle ear</td>
<td>Abdulaziz Al-mahallawi</td>
<td>Cairo University, Egypt</td>
</tr>
<tr>
<td>PNDDS13</td>
<td>Loco-regional breast cancer therapy through in situ thermosensitive Tamoxifen citrate niosomal gels</td>
<td>Dalia Samuel Shaker</td>
<td>Future University, Egypt</td>
</tr>
<tr>
<td>PNDDS14</td>
<td>Ecofreindly synthesis of silver nanoparticles using Fenugreek seeds’ aqueous extracts and its antimicrobial properties</td>
<td>Asmaa Ashour</td>
<td>Alexandria University, Egypt</td>
</tr>
<tr>
<td>PNDDS15</td>
<td>Preparation and optimization of Lacidipine nanosuspensions by antisolvent sonoprecipitation technique using box-behken design</td>
<td>Ahmed Fares Roshdy</td>
<td>Cairo University, Egypt</td>
</tr>
<tr>
<td>PNDDS16</td>
<td>Coated prolonged release minitablets with Carbamazepine</td>
<td>Maja Szczepańska</td>
<td>Medical University of Gdansk, Poland</td>
</tr>
<tr>
<td>PNDDS17</td>
<td>Synthesis, drug release and biological evaluation of new anticancer drug-bioconjugates containing Somatostatin backbone cyclic analog as a targeting moiety</td>
<td>Boris Redko</td>
<td>Ariel University, Israel</td>
</tr>
<tr>
<td>PNDDS18</td>
<td>Bio-labile pepidyl delivery systems towards sequential drug release</td>
<td>Elena Ragozin</td>
<td>Ariel University, Israel</td>
</tr>
<tr>
<td>PNDDS19</td>
<td>Development of novel synthetic approaches for synthesis of peptide drug candidates</td>
<td>Andri Bazylevich</td>
<td>Ariel University, Israel</td>
</tr>
<tr>
<td>PNDDS20</td>
<td>A novel approach to determine the rheological properties of the gel layer of swollen hydrophilic matrix tablets</td>
<td>Rania Hamed</td>
<td>Al-Zaytoonah University of Jordan, Jordan</td>
</tr>
</tbody>
</table>
In-vitro characterization of gambogenic acid bound nanobioconjugated target oriented drug carrier system for pancreatic cancer  
Sennur Gorgulu Kahyaoglu, Anadolu University, Turkey

Water quality and usage for reconstitution of antibiotics  
Mohamed Yehia Abouleish, American University of Sharjah, UAE

Formulation and in-vitro/in-vivo evaluation of buccoadhesive discs for controlled release of calcium channel antagonist  
Mohamed Haider, University of Sharjah, UAE

Electrically assisted transdermal drug delivery of Ovalbumin  
Ahlam Zaid Alkilani, Zarqa University, Jordan

Simulating the surface tension of the gastrointestinal fluid to enhance the dissolution of the weakly basic BCS class II drugs  
Rania Hamed, Al-Zaytoonah University of Jordan, Jordan

Some pyrimidine derivatives has cytotoxic and anticancer properties against A549 lung adenocarcinoma  
Bahar Demir, Anadolu University, Turkey

Formulation and characterization of Oregano microparticles prepared by spray-drying technology  
Juste Baranauskaite, Lithuanian University of Health Sciences, Lithuania

Does the change in interfacial tension caused by rosemary extract and some of its active ingredients affect the stability of multiple emulsion?  
Ugne Cizauskaite, Lithuanian University of Health Sciences, Lithuania

Synthesis of novel α-naphthol hydroxamate derivatives as anticancer agents  
Hafiz Antar Makeen, Jazan University, KSA

Design and Synthesis of Novel Non CYP 2D6 mediated Tamoxifen Analogues  
Nehal Hany Aly Elghazawy, German University in Cairo, Egypt

Comparison between two batches of Acetylsalicylic Acid using Sedem diagram to compare the suitability for direct compression  
Marc Sune-Pou, University of Barcelona, Spain

Day 3  March 09, 2016

Burgos

Keynote Forum

09:30-09:55  Amiram Goldblum  
The Hebrew University of Jerusalem, Israel

Track 3: Recent Advances in Drug Delivery Technology
Track 7: Major Challenges in Drug Delivery System
Track 11: Medical Devices for Drug Delivery

Session Chair: Amiram Goldblum, The Hebrew University of Jerusalem, Israel
Session Chair: B B Barik, Jazan University, KSA

Session Introduction

09:55-10:15  Enhanced delivery of DNA-based vaccines and immunotherapeutics through next-generation electroporation devices  
Paul Fisher, Inovio Pharmaceuticals Inc., USA

10:15-10:35  Application of high pressure technology for the development of intranasal delivery systems  
Catarina Duarte, iBET, Portugal

10:35-10:55  Targeted inorganic nanodevices for breast cancer diagnosis and therapy  
Luísa Fiandra, University of Milan, Italy

Networking & Refreshments Break 10:55-11:10 @ Salamanca

11:10-11:30  Composite hydrogels: An innovative approach for controlled release of hydrophobic drugs  
Havazelet Bianco-Peled, Technion-Israel Institute of Technology, Israel

11:30-11:50  Preparation and in-vitro/in-vivo evaluation of Metformin hydrochloride rectal dosage form  
Abdelazim Zaghloul, Kuwait University, Kuwait

Track 8: Physiological Considerations
Track 9: Vaccine Drug Delivery Systems
Track 10: Biotherapeutics-Drug Discovery and Development

Session Chair: Osama Ibrahim, Bio Innovation, USA
Session Chair: Helen McCarthy, Queen's University Belfast, UK

11:50-12:10  Expression of shiga-like toxin fused to Vascular Endothelial Growth Factor (VEGF/SLT) in E. coli for targeting angiogenesis  
Osama Ibrahim, Bio Innovation, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:10-12:30</td>
<td>A new technology for DNA vaccination: RALA peptide-mediated gene delivery via dissolving microneedles&lt;br&gt;Helen McCarthy, Queen’s University Belfast, UK</td>
</tr>
<tr>
<td>12:30-12:50</td>
<td>Nanotechnology and mucosal vaccines&lt;br&gt;José Crecente Campo, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Spain</td>
</tr>
<tr>
<td>12:50-13:10</td>
<td>Synthesis and evaluation of selected benzimidazole derivatives as potential antimicrobial agents&lt;br&gt;Fatmah Alasmary, King Saud University, KSA</td>
</tr>
<tr>
<td></td>
<td>Lunch Break 13:10-13:55 @ Salamanca</td>
</tr>
<tr>
<td>13:55-14:10</td>
<td>Development of a peptide-based, multifunctional gene delivery vector for metastatic prostate cancer&lt;br&gt;Stephen Loughran, Queen’s University Belfast, UK</td>
</tr>
<tr>
<td>14:10-14:25</td>
<td>Gold nanoparticle for macrophage targeting of Stavudine&lt;br&gt;Hinojal Zazo Gamez, Universidad de Salamanca, Spain</td>
</tr>
<tr>
<td>14:25-14:40</td>
<td>An investigation into the stability and aqueous solubility of amorphous solid dispersions of BCS class II drugs&lt;br&gt;Shrawan Baghel, Waterford Institute of Technology, Ireland</td>
</tr>
<tr>
<td>14:40-14:55</td>
<td>Local mucoadhesive drug delivery approach for furazolidone against Helicobacter pylori&lt;br&gt;Muhammad Irfan Alam, University of Sunderland, UK</td>
</tr>
<tr>
<td>14:55-15:10</td>
<td>NanoZYME technique applied to antioxidant enzyme, SOD, has high potential in the treatment of diseases related to oxidative stress&lt;br&gt;Anton Aleksashkin, Lomonosov Moscow State University, Russia</td>
</tr>
<tr>
<td></td>
<td>B2B Meetings</td>
</tr>
<tr>
<td></td>
<td>Award Ceremony</td>
</tr>
<tr>
<td></td>
<td>Networking &amp; Refreshments Break 15:25-15:40 @ Salamanca</td>
</tr>
</tbody>
</table>

**Bookmark your dates**

**10th International Conference and Exhibition on**

**Pharmaceutics & Novel Drug Delivery Systems**

**March 13-15, 2017  London, UK**

ABOUT:
ACDIMA BioCenter is a Contract Research Organization (CRO), established by ACDIMA (Arab Company for Drug Industry and Medical Appliances), a Pan-Arab shareholding company established by a resolution from the Arab Economic Unity Council on March 6, 1976. ACDIMA BioCenter was founded in 2000 and headquartered in Amman-Jordan to provide principally bioequivalence testing services to the pharmaceutical industry. Our mission is to deliver quality services of world class level to the pharmaceutical companies clients throughout the globe. ACDIMA BioCenter is the joint-articulation of effective cost with high quality standards and top reputation.

OUR LOGO
LOGO
The symbolic meaning of the anticlockwise semicircle arrows reads our revolutionary and extraordinary endeavors to make the difference and change the status quo.
Thematic colours of the logo are Blue and Purple. Blue is a colour often synonymous with healthcare which inspires vigor and wellbeing. The purple is to confer our passion.

SLOGAN
“Strategic Alignment for Myriad Advancements”.

MISSION
Is to make sure that our clients and partners are delivering their products effectively and help in speeding up the process, which in turn will maximize profits on their investments.

VISION
Is to be the pioneer and the leader in Jordan and the region by constantly focusing on innovating our products and services, delivering them with first-rate quality with the continual improvement of all of our business aspects.

SERVICES
- Bioanalytical Services
- Data Management Services
- Clinical Services
- Medical Laboratory Services
- Quality Assurance Services

Contact Us
Rabab F. Tayyem, PhD.
Executive Director/CEO
ACDIMA Center for Bioequivalence and Pharmaceutical Studies
Tel.: + 962 6 582 1618 | Fax: + 962 6 585 3719
Mobile: + 962 79 5616375
P.O. Box 925161 Amman 11190 Jordan
E-mail: rabab@acdima.com; biocenter@acdima.com
www.acdimabiocenter.com
Mission Statement

Our vision is to be globally renowned as a scientific leader and high quality provider of products and services in the field of ADME/Tox related transporters.

Our mission is to help our customers achieve their goals by providing them with products, services and consulting associated with ADME/Tox related transporters.

With over 15 years of experience, 80 transporter scientists, 40 of which are PhDs, and 450 clients in more than 40 countries, SOLVO is the leading worldwide provider of transporter assay Services and Products. During the past 15 years we have developed more than 130 transporter assays, both in vitro as well as in vivo, based on the latest results in transporter science, the needs of the pharmaceutical industry and the guidelines for drug drug interaction studies by the FDA and EMA. We have published more than 50 scientific papers, and performed thousands of assays in-house. With an in-house bio-analytical team, continuous R&D efforts, and highly specialized personnel, we can support your program with unmatched quality and expertise now and in the future.

About Solvo

• Mission Statement
• Why SOLVO
• Leadership
• Grants
• Awards & Prizes
• Career

Knowledge Center

• Transporter Book
• All about Transporters
• Pharmacological Barriers
• Publications
• Webinars
• Download Center
• PrediGuide - your free online transporter guide
• Patents
• BDDCS
• FAQ
• Science Letters
• Meet the Experts Conferences
• ReACTS

Regulatory Guidance

• Regulatory Guidance for Drug Interaction Studies
• Take home messages from the ITC papers

Services

• Aqueous Solubility Services
• Barrier Model Services
• Efflux Transporter Services
• In Vivo ADME Services
• LC/MS-MS Quantification of Transporter Proteins
• Transporter Consultancy Services
• Uptake Transporter Services

Products & Services

• Recent Developments
• Products
• Services
• Search by Transporters
• Technologies
• Think Twice

Contact Us

Péter Krajcsi, Ph.D.
Chief Scientific Officer
krajcsi@solvo.com
+36 23 503 944

Csilla Kegyes
Senior Sales Manager
Europe: France, Italy, Portugal, Spain, Germany
krajcsi@solvo.com
Phone: +36 23 503 940, +36 30 559 0688

http://www.solvobiotech.com/
Objective
Carrying out fundamental research and generic/infrastructural technology research and development in the field of materials science, and with improving the level of materials science and technology.

Research fields
- Materials for Energy and Environment
- Nanoscale Materials
- Advanced Key Technologies
- Information of our research - fields, activities and organization
- NIMS is a public institute specializing in materials research. As such, it is expected to achieve the policies laid out by the Japanese government in the Science and Technology Basic Plan and its own 5-year Mid-term Program based thereon, and to contribute to materials research and the enhancement of science and technology. Although the Science and Technology Basic Plan and NIMS Mid-Term Program are established in consideration of social needs, in recent years, solutions to global problems, as exemplified by the environment, energy, and resources, from the field of materials research have been particularly desired.

NIMS is engaged in a diverse range of materials research, with emphasis on responding to these social needs.

Research Fields
- Research for social needs, advanced key technologies and new materials

Research Project
- Research Project on the 3rd Mid-Term Plan

Research Organization
- A new system of 3 research divisions divided by specialization and fluid assignment of staff

Research Centers
- NIMS International Research Centers and the Corporate Collaboration Joint Research Centers actively grapple with problem-solving and outcome-oriented research.

Researcher
- Link to NIMS researcher database “SAMURAI”

Research Database
- Databases collecting information on NIMS researchers, published papers, patents, and research-related information

Contact Us
Akemi Hoshikawa
Nanotechnology Innovation Station
National Institute for Materials Science 1-2-1, Sengen, Tsukuba, Ibaraki 305-0047, JAPAN
Tel: +81-29-859-2000(ex.8712)  Fax: +81-29-859-2475
HOSHIKAWA.Akemi@nims.go.jp

Contact Us
National Institute for Materials Science (NIMS)
1-2-1 Sengen, Tsukuba-city Ibaraki 305-0047 JAPAN
info@nims.go.jp

http://www.nims.go.jp/
Lanyard Sponsor:

AMERICAN ELEMENTS
THE MATERIALS SCIENCE MANUFACTURER®

ROQUETTE

Collaborations

CiMUS
Center for Research in Molecular Medicine and Chronic Diseases

وزارة الصحة
Ministry of Health

UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

Media Partners:

fip International Pharmaceutical Federation

NIA Nanotechnology Industries Association

BREC

PharmaVision

The Pharma Review®

BENTHAM SCIENCE